ALCLS Cellectis S.A.

1.065USD0.9710 EUR · EPA-0.97%Mkt Cap: 108.27M USDP/E: —

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and g…

Institutional holders1 on file

Key Statistics

Company
Market Cap108.27M USD
Enterprise Value-24.27M USD
Revenue (TTM)32.10M USD
Gross Profit63.15M USD
Net Income (TTM)-67.59M USD
Revenue/Share0.32 USD
Last Price1.065 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees224
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0010425595
Valuation
P/E (Trailing)—
P/E (Forward)-0.62
PEG—
EV/EBITDA0.20
EV/Revenue-0.76
P/S3.08
P/B-6.29
EPS (TTM)-1.07 USD
EPS (Forward)-1.58 USD
52W Range
0.98162% of range5.210
52W High5.210 USD
52W Low0.9816 USD
Profitability
Gross Margin86.57%
Oper. Margin-384.93%
EBITDA Margin0.00%
Profit Margin-92.66%
ROE-89.05%
ROA-20.82%
ROIC—
ROCE-18.48%
Growth
Revenue Growth-85.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.40M USD
CapEx (TTM)3.53M USD
FCF Margin—
FCF Yield—
Net Debt-120.82M USD
Net Debt/EBITDA1.08
Net Debt/FCF—
Balance Sheet
Debt/Equity1.20
Current Ratio1.16
Quick Ratio1.12
Book Value/Sh-0.16 USD
Cash/Share1.46 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)7.129 USD
Upside (mean)+569.4%
Target Range7.129 USD – 7.129 USD
# Analysts1
Ownership
Shares Out.72.73M
Float67.30M
Insiders48.01%
Institutions12.29%
Technical
SMA 501.315 (-19.0%)
SMA 2002.768 (-61.5%)
Beta—
S&P 52W Chg12.00%
Avg Vol (30d)459.70K
Avg Vol (10d)692.35K
Technical Indicators
RSI (14)41.0
MACD-0.0574
MACD Signal-0.0681
MACD Hist.+0.0107
BB Upper1.355 USD
BB Middle1.145 USD
BB Lower0.9361 USD
BB Width36.57%
ATR (14)0.1198 USD
Vol Ratio (20d)0.21x

About Cellectis (EPA: ALCLS)

›

Cellectis (EPA: ALCLS) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 224 employees.

The shares were at 0.9710 EUR on 19 November 2026, down 77.4% over 52 weeks. Its 52-week range is 0.8950 EUR to 4.750 EUR: the price is 79.6% below the high and 8.5% above the low.

Its market capitalisation is 98.72M EUR.

Cellectis reports return on equity of -89.1%, an operating margin of -384.9% and revenue down 85.4% year over year.

It holds more cash than debt, a net cash position of 120.82M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.